Target intelligence / Profile preview

Neural EGFL-like protein 1 (NELL1)

Target
NELL1
Molecular classification
Growth factor, Secreted glycoprotein, Osteogenic regulatory protein, Signal transduction molecule, Other
01

Overview

Neural EGFL-like protein 1 (NELL1) is a secreted osteogenic growth factor primarily expressed in skeletal tissues, with powerful effects on bone and cartilage formation, stem cell differentiation, and inhibition of inflammation. Its molecular mechanism involves binding to integrin β1, acting as a ligand for receptors such as CNTNAP4 and Robo2, and driving differentiation via key developmental signaling pathways (MAPK, Wnt/β-catenin, Hedgehog, RUNX family, Notch). It has shown therapeutic potential in preclinical animal models for bone regeneration and osteoarthritis, often in synergy with BMP-2, with the advantages of being anti-adipogenic, anti-inflammatory, and promoting vascularization. Modulation of NELL1 holds promise for treating bone loss diseases, though challenges remain regarding biological stability and potential adverse effects with overexpression.

Other names
Nel-related protein 1NEL-like protein 1NELL1Neural epidermal growth factor-like 1Protein kinase C-binding protein NELL1FLJ45906
02

Mechanism of action

Stimulates bone formation via activation of several pathways: MAPK signaling, Wnt/β-catenin pathway, Hedgehog signaling, RUNX2 and RUNX3 transcription factors, Integrin β1-mediated cell adhesion, Modulation of Notch pathway (with isoforms). Inhibits adipogenesis and modulates inflammation in tissue repair.

03

Biological functions

Osteogenesis (bone formation)Chondrogenesis (cartilage formation)Regulation of mesenchymal stem cell differentiationInhibition of adipogenesis (prevents fat cell formation)Modulation of inflammation (especially in context of arthritis)Regulation of craniofacial and skeletal development
04

Disease associations

Bone regeneration (fracture healing, osteoporosis)Osteoarthritis (disease-modifying potential)Craniosynostosis (involved in abnormal suture closure in skull)
05

Safety considerations

Biological stability and pharmacokinetic limitationsOverexpression may cause craniofacial abnormalities and excessive bone apoptosisModulation of apoptosis in osteoblasts with overexpression
06

Interacting drugs

Bone morphogenetic protein 2 (BMP-2)
07

Biomarkers

Bone mineral density (BMD)Trabecular Bone Score (TBS)Genetic variants in NELL1 (SNPs associated with osteoporosis risk)

Beyond the preview

Go deeper on Neural EGFL-like protein 1 (NELL1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neural EGFL-like protein 1 (NELL1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call